MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.58
+0.15
+2.67%
Closed 16:00 02/19 EST
OPEN
5.50
PREV CLOSE
5.43
HIGH
5.70
LOW
5.50
VOLUME
186.73K
TURNOVER
--
52 WEEK HIGH
9.76
52 WEEK LOW
4.350
MARKET CAP
94.96M
P/E (TTM)
-2.1018
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CATB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CATB News

  • Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option of 5.29M Common Shares At $5/share
  • Benzinga.02/03 21:06
  • Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
  • Business Wire.02/03 21:05
  • The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
  • Benzinga.01/30 14:26
  • FB, TSCO among premarket losers
  • Seeking Alpha - Article.01/30 14:17

More

Industry

Biotechnology & Medical Research
+1.22%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About CATB

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
More

Webull offers Catabasis Pharmaceuticals Inc (CATB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.